SEARCH

SEARCH BY CITATION

References

  • 1
    Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol 2010; 16: 25919.
  • 2
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 3
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 87685.
  • 4
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC I trial. Gastroenterology 2006; 130: 32333.
  • 5
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 12329.
  • 6
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 7
    Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 2009; 58: 9408.
  • 8
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009; 58: 492500.
  • 9
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab. Ann Intern Med 2007; 146: 82938.
  • 10
    Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 41623.
  • 11
    Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010; 32: 122839.
  • 12
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357: 22838.
  • 13
    Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005; 129: 80718.
  • 14
    Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2011; 9: 4217.
  • 15
    Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 2009; 137: 162840.
  • 16
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 138395.
  • 17
    Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 13638.
  • 18
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 2002; 123: 70713.
  • 19
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24(Suppl 170): 26.
  • 20
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A): 536.
  • 21
    Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006; 55(Suppl i): i115.
  • 22
    Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 23
    Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009; 15: 1295301.
  • 24
    Szamosi T, Banai J, Lakatos L, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and non-smokers with Crohn’s disease, while smoking prevents colectomy in UC. Eur J Gastroenterol Hepatol 2010; 22: 8729.
  • 25
    Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn’s disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 57783.
  • 26
    Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010; 138: 4638.
  • 27
    Colombel JF, Rutgeerts P, Sandborn WJ, et al. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn’s disease: results from EXTEND. Gastroenterology 2010; 138(SupplS): T1239.
  • 28
    Lakatos PL, Kiss LS, Palatka K, et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn’s disease. Inflamm Bowel Dis 2011; 17: 76777.
  • 29
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 2002; 123: 70713.
  • 30
    Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther 2003; 17: 14517.
  • 31
    Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. Am J Gastroenterol 2002; 97: 235763.
    Direct Link:
  • 32
    Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn’s disease. Inflamm Bowel Dis 2004; 10: 34651.
  • 33
    Triantafillidis JK, Mantzaris G, Karagiannis J, et al. Similar response to adalimumab in patients with active Crohn’s disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi 2010; 114: 8590.
  • 34
    Chaparro M, Panes J, García V, et al. Long-term durability of response to adalimumab treatment in Crohn’s disease. Gastroenterology 2010; 138: S-689.
  • 35
    Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther 2010; 31: 1296309.
  • 36
    Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 18618.
  • 37
    Loftus EV Jr, Pan X, Zurawski P, Mulani P, Chao J. Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn’s disease in the United States. J Crohns Colitis 2009; 3: S24.